Roche Holding AG Participation (ROG)

344.55
0.00(0.00%)
  • Volume:
    760,844
  • Bid/Ask:
    344.55/344.60
  • Day's Range:
    341.20 - 346.65
  • Type:Equity
  • Market:Switzerland
  • ISIN:CH0012032048
  • S/N:1203204

ROG Overview

Prev. Close
344.55
Day's Range
341.2-346.65
Revenue
89.04B
Open
343.1
52 wk Range
290.55-359.1
EPS
16.25
Volume
760,844
Market Cap
294.34B
Dividend (Yield)
9.10
(2.56%)
Average Volume (3m)
1,190,425
P/E Ratio
21.21
Beta
0.88
1-Year Change
7.45%
Shares Outstanding
854,260,903
Next Earnings Date
19 Oct 2021
What is your sentiment on Roche Holding AG Participation?
or
Market is currently closed. Voting is open during market hours.

Roche Holding AG Participation News

Roche Holding AG Participation Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralStrong Buy
Technical IndicatorsStrong SellStrong SellBuyStrong SellStrong Buy
SummaryStrong SellStrong SellNeutralSellStrong Buy

Roche Holding AG Participation Company Profile

Roche Holding AG Participation Company Profile

Employees
101465

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.